A5001474630- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Urinary Bladder and Prostate Research
- Bladder and Urothelial Cancer Treatments
- Urologic and reproductive health conditions
- Hormonal and reproductive studies
- Sexual function and dysfunction studies
- Pelvic floor disorders treatments
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Lipids, and Metabolism
- Kidney Stones and Urolithiasis Treatments
- Ureteral procedures and complications
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Nephrotoxicity and Medicinal Plants
- Health, Medicine and Society
- Genital Health and Disease
- Pharmacology and Obesity Treatment
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Urinary Tract Infections Management
- MRI in cancer diagnosis
- Renal and Vascular Pathologies
- Pediatric Urology and Nephrology Studies
Erasmus Hospital
2015-2025
Université Libre de Bruxelles
2016-2025
Institut Jules Bordet
2017-2024
Grand Charleroi Hospital
2011-2023
CRV (Netherlands)
2020
Centre Alexandre Koyré
2019
Leefmilieu Brussel
2017-2019
KU Leuven
2019
Centre Hospitalier Universitaire Brugmann
2018
University of California, Irvine
2018
<h3>Importance</h3> DCVAC/PCa is an active cellular immunotherapy designed to initiate immune response against prostate cancer. <h3>Objective</h3> To evaluate the efficacy and safety of plus chemotherapy followed by maintenance treatment in patients with metastatic castration-resistant cancer (mCRPC). <h3>Design, Setting, Participants</h3> The VIABLE double-blind, parallel-group, placebo-controlled, phase 3 randomized clinical trial enrolled mCRPC among 177 hospital clinics US Europe between...
We aimed to evaluate the role of prostate-specific membrane antigen (PSMA) PET/CT for response assessment and outcome prediction in patients with metastatic castration-resistant prostate cancer (mCRPC) treated androgen receptor pathway inhibitors (ARPIs), including abiraterone acetate or enzalutamide. <b>Methods:</b> retrospectively analyzed 30 ARPI-treated mCRPC who underwent <sup>68</sup>Ga-PSMA-11 within 8 wk before (baseline) 12 ± 4 after treatment initiation. Total PSMA tumor volume was...
To externally validate the currently available nomograms for predicting lymph node invasion (LNI) in patients with prostate cancer (PCa) and to assess potential risk of complications extended pelvic dissection (ePLND) when using recommended threshold.A total 14 921 patients, who underwent radical prostatectomy ePLND at eight European tertiary referral centres, were retrospectively identified. After exclusion incomplete biopsy or pathological data, 12 009 included. Of these, 609 had undergone...
Background: Varicocele is a common condition in men that can lead to several clinical problems. Treatment modalities include surgical and non‑surgical methods. There has been no randomized controlled trial proving the superiority of one treatment approach over another. Materials methods: We conducted an 8‑year retrospective analysis varicocele embolization procedures at our department Interventional Radiology. Demographic data, procedure details, success complications were collected....